Weekly Recap | Beigene -1.01%, most brokers rate it buyWeekly Review·Oct 10, 2026 at 07:17 AMONC+1.24%
Weekly Recap | ArriVent Biopharma -40.82%, Phase 3 trial misses endpointWeekly Review·Oct 10, 2026 at 06:05 AMAVBP+0.12%
